Makes sense to move the diagnostics division to a new office. As a revenue generator, it is really not an incubator program. MANF and Eltoprazine can stay at Janssen under the therapeutic division in the incubator program. I also think the 1-Bil shares is for a spin off. GC specifically mentioned in his blog about spin off in the exact same bullet as his mention of Lympro partnership or data. Can't remember right now but it was within the same thought so I think they are linked.